An unwritten "founder code" exists in Silicon Valley. A key violation is abandoning a well-performing, venture-backed company to start a new one in a hotter space (e.g., AI). This prematurely sells out investors and violates the trust placed in the founder.

A venture capitalist's career security directly impacts the founder relationship. VCs with a proven track record (like Sequoia's Andrew Reed) act as supportive partners. In contrast, junior or less successful VCs often transfer pressure from their own partnerships onto the founder, creating a stressful and counterproductive dynamic.

For a seed investor, the most critical downside protection isn't a legal term in a document, but the implicit guarantee that the founder will never quit. This psychological commitment is the ultimate, unwritten liquidation preference.

Founders are warned against being manipulated by late-stage investors who pressure them to strip rights (like pro-rata) from early backers. This disloyalty breaks trust and signals to new investors that the founder can also be manipulated, setting a dangerous precedent for future governance.

Beyond product-market fit, there is "Founder-Capital Fit." Some founders thrive with infinite capital, while for others it creates a moral hazard, leading to a loss of focus and an inability to make hard choices. An investor's job is to discern which type of founder they're backing before deploying capital that could inadvertently ruin the company.

Psychedelics can serve as a high-stakes litmus test for a founder's conviction. An investor might see a founder who hasn't used them as a risk, as a trip could cause a career pivot. Conversely, a founder who continues their B2B SaaS venture post-trip is proven to be a "true believer."

Andreessen observes that founders under pressure who turn to psychedelics may find personal peace and happiness, but this often leads them to abandon their ambitious ventures. This highlights a fundamental tension between optimizing for personal well-being versus professional impact.

Investors can be non-committal. To cut through ambiguity, founders must create a forcing function by directly asking for the term sheet. If the investor stalls or deflects, it's a negative signal, and the founder should move on.

A core challenge for psychedelic drug development is 'functional unblinding.' The compounds are so powerfully psychoactive that patients can easily guess treatment allocation, undermining the placebo control. This creates a strong expectation bias that may inflate perceived efficacy and complicate trial interpretation.